"Antitubercular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.
| Descriptor ID |
D000995
|
| MeSH Number(s) |
D27.505.954.122.085.255
|
| Concept/Terms |
Antitubercular Agents- Antitubercular Agents
- Agents, Antitubercular
- Antitubercular Drugs
- Drugs, Antitubercular
- Tuberculostatic Agents
- Agents, Tuberculostatic
|
Below are MeSH descriptors whose meaning is more general than "Antitubercular Agents".
Below are MeSH descriptors whose meaning is more specific than "Antitubercular Agents".
This graph shows the total number of publications written about "Antitubercular Agents" by people in this website by year, and whether "Antitubercular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 5 | 7 |
| 1996 | 1 | 2 | 3 |
| 1997 | 1 | 2 | 3 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 3 | 0 | 3 |
| 2002 | 5 | 2 | 7 |
| 2003 | 0 | 1 | 1 |
| 2004 | 3 | 2 | 5 |
| 2005 | 2 | 1 | 3 |
| 2006 | 2 | 1 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 3 | 1 | 4 |
| 2009 | 2 | 5 | 7 |
| 2010 | 2 | 2 | 4 |
| 2011 | 7 | 3 | 10 |
| 2012 | 3 | 5 | 8 |
| 2013 | 5 | 4 | 9 |
| 2014 | 1 | 5 | 6 |
| 2015 | 2 | 2 | 4 |
| 2016 | 6 | 8 | 14 |
| 2017 | 7 | 0 | 7 |
| 2018 | 10 | 4 | 14 |
| 2019 | 9 | 5 | 14 |
| 2020 | 6 | 6 | 12 |
| 2021 | 1 | 4 | 5 |
| 2022 | 1 | 4 | 5 |
| 2023 | 0 | 5 | 5 |
| 2024 | 4 | 3 | 7 |
| 2025 | 5 | 3 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antitubercular Agents" by people in Profiles.
-
Decentralising TB diagnosis and contact management: impact on detection and preventive treatment in children. Int J Tuberc Lung Dis. 2025 Jun 27; 29(7):312-317.
-
Tuberculosis in adult migrants in Europe: a TBnet consensus statement. Eur Respir J. 2025 Mar; 65(3).
-
Fluoroquinolone Resistance in Drug-Resistant Tuberculosis, Kharkiv, Ukraine, 2019-2023. Emerg Infect Dis. 2025 Mar; 31(3):615-617.
-
Shifting tuberculosis dynamics in the EU/EEA: geographical and drug resistance trends among people of foreign origin, 2019 to 2023. Euro Surveill. 2025 Mar; 30(11).
-
A novel method for detecting Lipoarabinomannan in urine with the promise of meeting the WHO target product profile for the diagnosis of tuberculosis. Tuberculosis (Edinb). 2025 May; 152:102619.
-
Completion, Safety and Tolerability of Once-weekly Isoniazid and Rifapentine for Tuberculosis Infection by Children and Adolescents. Pediatr Infect Dis J. 2025 Feb 14; 44(8):755-758.
-
Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis. Lancet Child Adolesc Health. 2025 02; 9(2):100-111.
-
Safety of 3-month rifampicin-isoniazid TPT in child household contacts in a community-based intervention. Int J Tuberc Lung Dis. 2025 02 01; 29(2):67-74.
-
High risk of drug-resistant tuberculosis in IGRA-negative contacts: should preventive treatment be considered? Infection. 2025 Aug; 53(4):1501-1506.
-
Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2025 Jan; 211(1):15-33.